Shuttle Pharma intends to use the net proceeds from the Offering to fund Shuttle Pharma’s Phase II clinical trial for its lead product candidate, for marketing and advertising services, and for ...

Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public ...

The offering is expected to close on or about March 13, 2025, subject to customary closing conditions. Nutrien intends to use the net proceeds from this offering to repay its US$500 million ...

A10 Networks' shares were sharply lower after the technology company priced a roughly $200 million offering of convertible debt. In morning trading, the security-and-infrastructure-solutions company's ...

Beam Therapeutics shares were 14% lower, at $24.60, after the company priced an underwritten offering with proceeds of $500 million. The biotechnology company said it is offering 16.2 million shares ...

of its 6.25% Series D Mandatory Convertible Preferred Stock (the “mandatory convertible preferred stock”) at a price to the public and liquidation preference of $50.00 per share. The offering ...